Reports Q3 revenue $1,000, consensus $100,000. “We remain laser focused on initiating our Phase 3 program and progressing Ixo-vec toward approval and commercialization,” stated Laurent Fischer, president and chief executive officer of Adverum Biotechnologies (ADVM). “Over the past year we’ve presented LUNA clinical data supporting what I believe to be the best-in-class product candidate for wet AMD patients. These data echo, and even improve upon, Ixo-vec’s robust and durable efficacy and favorable long-term safety profile, which have been demonstrated out to 3 years. Later this quarter we look forward to presenting the LUNA 52-week data alongside the 4-year OPTIC data. We are closing in on our goal to bring a potentially transformational gene therapy to wet AMD patients, who suffer from a life-long disease that, even with the best available agents, requires frequent injections into the eye.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADVM:
- Adverum Biotechnologies appoints Jason Mitchell as CCO
- Adverum Biotechnologies participates in a conference call with Oppenheimer
- Adverum Biotechnologies management to meet with Oppenheimer
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Adverum Biotechnologies reports inducement grants under Nasdaq listing rule
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
